AstraZeneca and Merck announced positive results from the randomized, double-blind, placebo-controlled, phase III SOLO-1 trial of Lynparza (olaparib) tablets.
NIH Director Jay Bhattacharya has taken a second big job.
Lynparza delays disease progression in phase III trial in first-line ovarian cancer
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Malcolm V. Brock, director of Clinical and Translational Research in Thoracic Surgery at Johns Hopkins Kimmel Comprehensive Cancer Center, grew up in Bermuda. His father insisted that his children branch outside the small island—the country has a population of just over 60,000 people—and challenge themselves abroad.
For decades, FDA commissioners sought to insulate the agency’s professional staff from political interference with regulatory decisions.
Bayer, the owner of the herbicide Roundup, offered $7.25 billion to settle thousands of lawsuits alleging that the product is responsible for causing cases of Non-Hodgkin lymphoma.
After leading unprecedented growth of St. Jude Children’s Research Hospital over the past 12 years, James R. Downing will step down as president and CEO in late 2026 as part of a planned leadership transition, St. Jude officials said.
Alice Soragni, an expert in patient-derived tumor organoids and functional precision oncology, has joined the University of Colorado Anschutz.
